500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

Fudan University

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT03695341

YOUNGBC-3

Details and patient eligibility

About

500mg Fulvestrant versus Everolimus plus Exemestane in MBC patients refractory to previous AI

Full description

Fulvestrant versus Everolimus plus Exemestane for patients with Metastatic Breast Cancer resistant to Aromatase Inhibitors: the clinical experience from real -world

Enrollment: 130 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients diagnosed with ER/PR+，HER2- Metastatic Breast Cancer
2. Patients who were refractory to previous Aromatase Inhibitors
3. Patients treated with Fulvestrant or Everolimus plus Exemestane in any line in metastatic setting in Fudan University Shanghai Cancer Center，starting from 2013.06.01-2016.06.01
4. Available medical history

Exclusion criteria

1.Incomplete medical history

Trial design

130 participants in 2 patient groups

Fulvestrant

Description:

Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15

Everolimus plus Exemestane

Description:

Everolimys 10 mg or 5 mg daily; Exemestane 25mg per day